Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ankyrins are a family of intracellular adaptor proteins that link integral membrane proteins to the spectrin-actin cytoskeleton in eukaryotic cells[1][2][5]. The ankyrin family is encoded by three genes in mammals—ANK1, ANK2, and ANK3—each producing multiple alternatively spliced variants, typically called Ankyrin-R (erythrocyte ankyrin), Ankyrin-B, and Ankyrin-G[2]. Ankyrins are characterized structurally by 24 tandem ankyrin repeats at the N-terminus—a protein–protein interaction module—followed by domains that bind spectrin, regulate protein interactions, and mediate intracellular signaling[1][2][3][4]. Ankyrins function as scaffold proteins, organizing protein complexes that include membrane transporters (e.g., Na⁺/K⁺ ATPase, voltage-gated sodium and potassium channels), cell adhesion molecules (L1-CAM), and signaling molecules, thus shaping and sustaining specialized plasma membrane domains such as those in neurons (axon initial segment and nodes of Ranvier) and cardiomyocytes[1][2][5]. Dysfunction or mutation of ankyrin genes is implicated in diseases including hereditary spherocytosis (a hemolytic anemia associated with ANK1 mutations), cardiac arrhythmia (ANK2), and may play a role in certain neurological or psychiatric conditions (e.g., ANK3 and bipolar disorder)[1][2][5]. Ankyrin itself is not considered a conventional drug target (such as a receptor, enzyme, ion channel, or transporter), but a structural component and scaffold, and is not currently targeted by any known therapeutic drugs[1][2][5]. Additional notes: - "Ankyrin" is a protein family, not a single defined molecule or a canonical therapeutic target. - The term "ankyrin repeat" describes a protein structural motif found in ankyrins and many other proteins[3][4]. - Each member (ANK1, ANK2, ANK3) may have more precisely defined disease roles and interaction partners. - If a precise target (such as a specific ankyrin subtype or disease-linked isoform) is intended, further context is required to yield structured drug-target data.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ankyrin.